IPP Bureau
FDA accepts Deciphera’s NDA for tirabrutinib in rare aggressive brain lymphoma
By IPP Bureau - February 18, 2026
The drug targets relapsed or refractory primary central nervous system lymphoma, a rare and aggressive form of non-Hodgkin lymphoma
Newron Pharmaceuticals bags up to €38 million to fuel Phase III ENIGMA-TRS program
By IPP Bureau - February 18, 2026
A final tranche of €12 million will follow, contingent on positive pivotal study results, with the share price calculated according to an agreed formula
QCIL to build 350+ bed state-of-the-art CARE Hospital in Nagpur
By IPP Bureau - February 18, 2026
USFDA issues Form 483 with 6 observations to Enzene Biosciences’ Chakan plant following PAI
By IPP Bureau - February 17, 2026
The Pre-Approval Inspection (PAI) was completed on February 13, 2026, and the company is initiating corrective actions.
Lupin partners with Spektus Pharma to commercialize DeslaFlex antidepressant in Canada
By IPP Bureau - February 17, 2026
DeslaFlex is an innovative antidepressant formulation developed by Spektus using the proprietary Flexitab oral drug-delivery platform
Sanofi Healthcare expands Hyderabad Global Hub, boosts capacity to 4,500 staff
By IPP Bureau - February 17, 2026
Backed by a multi-hundred-million-dollar investment, the expansion underscores Sanofi’s long-term commitment to India’s thriving life sciences ecosystem
Lilly’s Retevmo shows major survival boost in early-stage RET fusion lung cancer
By IPP Bureau - February 17, 2026
The trial, which compared Retevmo to placebo, met its primary endpoint with a “highly statistically significant and clinically meaningful improvement” in investigator-assessed EFS for patients with stage II–IIIA disease
Roche’s Gazyva hits major milestone in rare kidney disease
By IPP Bureau - February 17, 2026
Primary membranous nephropathy is a chronic autoimmune disease that attacks the kidneys’ filtering units
Ind-Swift Labs to pump Rs. 40 crore into Samba facility for global expansion
By IPP Bureau - February 17, 2026
The enhancements will improve environmental sustainability, strengthen material governance, and boost utility reliability
Novartis’ Vanrafia shows promise in slowing kidney decline in IgA nephropathy
By IPP Bureau - February 17, 2026
Vanrafia, a potent endothelin A receptor antagonist, received accelerated approval in the US and China in 2025 for reducing proteinuria in adults with IgAN
Mankind Pharma overhauls global supply chain with AI
By IPP Bureau - February 17, 2026
The initiative, delivered in collaboration with Accenture, integrates digitally enabled operating models powered by advanced analytics and AI across the company’s procurement, manufacturing, and distribution networks
Alto Neuroscience completes enrollment in Phase 2 trial for first-of-its-kind schizophrenia cognitive treatment
By IPP Bureau - February 17, 2026
Alto met its enrollment goal with 83 patients across 13 US clinical sites
HanchorBio scores first FDA orphan drug tag for gastric cancer therapy
By IPP Bureau - February 17, 2026
The designation for HCB101covers all forms of gastric cancer, including advanced gastric adenocarcinoma in both HER2-positive and HER2-negative patients
Beyfortus cuts RSV hospitalizations across two seasons in landmark study
By IPP Bureau - February 17, 2026
The NIRSE-GAL study, conducted in Galicia, Spain, is the first real-world, population-based investigation of a universal RSV immunization program spanning two consecutive seasons
